Skip to main content
Fig. 2 | Translational Medicine Communications

Fig. 2

From: Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy

Fig. 2

a Pulsed, mature DC yields. The recovery efficiency is depicted as a function of the peptide used in pulsing procedures. The recovery efficiency was measured as a percent of iDC. obtained after maturation and pulsing (mDC) using the formula mDC/iDC × 100. b mDC viability. The viability of pulsed, mDC before and after freezing and thawing was measured using the trypan-blue exclusion method. Histograms show the percent viable cells calculated with the following formula (total cells – trypan blue-positive cells) / (total cells) × 100. Each count was performed in triplicate (from 3 aliquots of the cell suspension), and bars represent the average of the replicates (confidence intervals ranged from +/− 5 to +/− 12% of the mean)

Back to article page